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Abstract: The first steps of leucine utilization are reversible deamination to !-ketoisocaproic acid (!-KIC) and irreversible
oxidation. Recently the regulatory role of leucine deamination over oxidation was underlined in rodents. Our aim was to
measure leucine deamination and reamination in the whole body, in respect to previously determined rates across individual
organs, in humans. By leucine and KIC isotope kinetics, we determined whole-body leucine deamination and reamination, and
we compared these rates with those already reported across the sampled organs. As an in vivo counterpart of the “metabolon”
concept, we analysed ratios between oxidation and either deamination or reamination. Leucine deamination to KIC was greater
than KIC reamination to leucine in the whole body (p = 0.005), muscles (p = 0.005), and the splanchnic area (p = 0.025). These rates
were not significantly different in the kidneys. Muscle accounted for ≈60% and ≈78%, the splanchnic bed for ≈15% and ≈15%, and
the kidney for ≈12% and ≈18%, of whole-body leucine deamination and reamination rates, respectively. In the kidney, percent
leucine oxidation over either deamination or reamination was >3-fold greater than muscle and the splanchnic bed. Skeletal
muscle contributes by the largest fraction of leucine deamination, reamination, and oxidation. However, in relative terms, the
kidney plays a key role in leucine oxidation.
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Résumé : La désamination réversible de l’acide !-céto-isocaproïque (!-KIC) et l’oxydation irréversible constituent les premières
étapes de l’utilisation de la leucine. On a récemment souligné chez les rongeurs l’importance du rôle de régulation de la
désamination de la leucine par rapport à l’oxydation. Nous avions comme objectif de mesurer la désamination et la réamination
de la leucine dans le corps entier, en regard de taux établis antérieurement dans des organes donnés chez l’humain. À l’aide de
la cinétique d’isotopes de leucine et du KIC, nous avons établi la désamination et la réamination de la leucine à l’échelle du corps
entier, et nous avons comparé ces taux à ceux qui ont déjà été rapportés dans les organes échantillonnés. Nous avons considéré
les ratios entre l’oxydation et la désamination ou la réamination comme étant une contrepartie in vivo du concept de « métabolon »,
et nous les avons analysés. La désamination de la leucine en KIC était plus importante que la réamination du KIC en leucine dans
le corps entier (p = 0,005), dans les muscles (p = 0,005) et dans le lit splanchnique (p = 0,025). Ces taux n’étaient pas nettement
différents dans les reins. Les muscles comptaient pour environ 60 et 78 % dans les taux respectifs de désamination et de
réamination de la leucine dans le corps entier, le lit splanchnique dans environ 15 et 15 % du total et les reins dans 12 et 18 % du
total. Le pourcentage d’oxydation de la leucine par rapport à sa désamination ou à sa réamination était plus de trois fois
supérieur dans les reins par rapport aux muscles et au lit splanchnique. Le muscle squelettique contribue dans la plus grande
mesure à la désamination, à la réamination et à l’oxydation de la leucine. Cependant, tout étant relatif, les reins jouent un rôle
clé dans l’oxydation de la leucine. [Traduit par la Rédaction]
Mots-clés : leucine, transamination, acides aminés ramifiés, cétoacides, muscles squelettiques, reins.
Introduction
The control of the catabolic flux of most amino acids takes place
at the first metabolic steps, i.e., at the transamination/deamina-
tion reactions (Nelson and Cox 2015). The term “transamination”
refers to the overall process of amino group transfer from a donor
amino acid to an accepting ketoacid, to form a daughter amino
acid. Conversely, “deamination” refers just to loss of an amino
group by a given amino acid, whereas “reamination” refers to the
capture of an amino group by a ketoacid to form an amino acid.
The transamination of leucine, valine, and isoleucine (branched-
chain amino acids; BCAA) plays a key role in nitrogen distribution
among nonessential amino acids and in nitrogen shunting either
to urea formation or to protein synthesis (Nelson and Cox 2015). At
variance with most amino acids, which are predominantly uti-
lized by the liver, BCAAs are thought to be mainly catabolized by
extrahepatic tissues (Nelson and Cox 2015; Cohen and Hekhuis
1941; Ichihara 1985; Miller 1961), above all skeletal muscle (Miller
1961; Adibi 1976; Brosnan and Brosnan 2006) and adipose tissue
(Brosnan and Brosnan 2006). Nevertheless, the relative role of
BCAA transamination vs. oxidation is incompletely defined. Re-
cent observations suggest that transamination plays a more im-
portant role than that previously assumed, on the control of BCAA
metabolism. Mitochondrial BCAA transaminases (BCAA-Tm) are
ubiquitary in animal tissues (Taylor and Jenkins 1966; Suryawan
et al. 1998). Furthermore, it has been recently demonstrated that
Received 29 June 2017. Accepted 11 August 2017.
G. Garibotto* and D. Verzola. Nephrology, Dialysis and Transplantation Clinic, Department of Internal Medicine, University of Genova, Genova, Italy;
IRCCS AOU San Martino-IST, Genova, Italy.
M. Vettore and P. Tessari.* Metabolism Division, Department of Medicine, University of Padova, Padova, Italy.
Corresponding author: Giacomo Garibotto (email: gari@unige.it).
*These authors contributed equally to this study.
Copyright remains with the author(s) or their institution(s). Permission for reuse (free in most cases) can be obtained from RightsLink.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
1
Can. J. Physiol. Pharmacol. 00: 1–6 (0000) dx.doi.org/10.1139/cjpp-2017-0439 Published at www.nrcresearchpress.com/cjpp on 11 September 2017.
Fn1
rich2/jpp-cjpp/jpp-cjpp/jpp99914/jpp0903d14z xppws S!3 2/13/18 10:31 Art: cjpp-2017-0439 Input-1st disk, 2nd ??
AUTHOR: Please be sure to check this proof file against the copy-edited 
manuscript and table file (cjpp-2017-0439ms.pdf). Please see the 22 
comments in the  cjpp-2017-0439ms.pdf file. 
Please be sure to only annotate this proof file. To expedite the process, only 
respond to queries that require corrections. 
I look forward to receiving your requested changes. Thanks!
mitochondrial BCAA-Tm and branched chain !-ketoacid dehy-
drogenase (BCKD) enzyme complexes associate to form a supra mo-
lecular entity (Islam et al. 2007), of the type originally defined as
“metabolon” (Robinson and Srere 1985), that provides a coordinated
control of the BCAA metabolic flux and oxidation. According to this
concept, the tissue-specific level of BCKD dehydrogenase, and the
phosphorylation state of the BCKD complex, regulate both BCAA-
carbon irreversible loss (i.e., oxidation) and rates and direction of
reamination/deamination. In BCAA-Tm knock-out mouse, it was con-
cluded that BCAA-Tm actually plays a key role in BCAA signaling and
anabolism, beyond that “classically” played by oxidation (Joshi et al.
2006).
Among the 3 BCAAs, leucine plays a pivotal role both as an
important anabolic signal and a regulator of protein turnover
(Buse and Reid 1975; Kimball and Jefferson 2004). In addition,
leucine kinetic is commonly taken as an index of whole-body and
organ protein turnover (Matthews and Bier 1983; Tessari 1994). So
far, however, only a few studies have provided data on whole-body
and organ leucine transamination and oxidation in humans.
Matthews et al. (1981) proposed a model of leucine deamination
and reamination at whole-body level, while Cheng et al. (1985)
reported estimates of these rates across the human forearm. More
recently, we reported the rates of leucine deamination, reamina-
tion, and oxidation across the leg, the splanchnic area, and the
kidney (Tessari et al. 1996). However, in that study, we did not
report some additional data, which were not analyzed at that time
yet, on whole-body leucine deamination and reamination, to which
organ rates could be compared.
This study aims to complete the picture of leucine deamination,
reamination, and oxidation rates across 3 major organs in hu-
mans, in comparison with the corresponding ones determined at
whole-body level. In addition, this study reports on a new model
to measure whole-body leucine deamination, based on the infu-
sion of an independent ketoisocaproic acid (KIC) tracer, concep-
tually similar to that previously used to estimate first pass
splanchnic leucine uptake and deamination (Biolo and Tessari
1997). The contributions of skeletal muscle, the splanchnic bed,
and the kidneys, to whole-body leucine deamination, reamination,
and oxidation, are also presented in the light of the “metabolon”
concept, based on a combined analysis of leucine transamination
and oxidation.
Material and methods
Subjects were enrolled between September 1993 and July 1994.
The subjects’ clinical characteristics, the inclusion criteria, and
the experimental design, had been previously reported (Tessari
et al. 1996), except for an additional subject (male gender, age
56 years, BMI 25.8 kg·m−2), whose data became available after the
publication of the original manuscript (Tessari et al. 1996). In
addition to the previously reported tracers, all subjects had also
been infused with the [2H3]-!-ketoisocaproic acid stable isotope
tracer ([!-D3-KIC] (>98% purity, obtained from Tracer Technolo-
gies, Somerville, Massachusetts, USA). All isotopes were dissolved
in sterile saline and proven to be sterile and pyrogen-free before
use. Studies were performed in the post-absorptive state. At 0800,
primed-continuous infusions of the leucine tracers were started
and carried out for 4 h (Tessari et al. 1996). The D3-KIC infusion
rate was 0.0343 ± 0.0051 (mean ± SE) "mol·kg−1·min−1. Isotope
priming doses were 30× the continuous infusion rates per minute.
Sample processing and analytical methods were performed as
described by Tessari et al. (1996) and Schwenk et al. (1984). We
employed a compartmental model in the analysis of the regional
leucine metabolic steps, as previously reported (Tessari et al. 1995,
1996) (see Supplementary Methods and Supplementary Fig. S11).
Arterial and venous concentrations and enrichments (Supple-
mentary Fig. S21) of leucine, KIC, and CO2 remained stable, indi-
cating that tracers and tracees were at steady state throughout the
study.
Statistical analysis
The data were reported as means ± SE. Organ as well as whole-
body kinetics data were normalized per 1.73 m2 of body surface
(Tessari et al. 1996). The Wilcoxon test for paired data was used
to compare the rates of leucine deamination and reamination
within each organ as well as in the whole body, using the Statis-
tical Software (Version 7.1, StatSoft Italia). In addition, the data
were analyzed also using the two-tailed Student’s t test for paired
data. To compare the percent contribution of each organ with
whole-body deamination or reamination rates, as well as the frac-
tion of leucine oxidation over either leucine deamination to KIC
or KIC reamination to leucine among the different organs, we
employed the one-way ANOVA followed by the Newman–Keuls
post hoc test. A p value less than 0.05 was considered statistically
significant.
Results
Leucine deamination and KIC reamination
The rates of whole-body leucine deamination to KIC were quite
similar using either Model 1 as reported by Matthews et al. (1981)
or Model 2 (based on the data calculated from the infusion of the
independent KIC tracer (Fig. 1).
Leucine deamination to KIC was greater than KIC reamination
to leucine at whole-body level (p = 0.005), in skeletal muscle
(p = 0.005), and in the splanchnic area (p = 0.025), whereas these
rates were not significantly different from each other in the kid-
neys (Fig. 2A), as previously reported (Tessari et al. 1996).
When expressed as percentage of whole-body rates, total skele-
tal muscle accounted for ≈60% of leucine deamination and ≈78% of
leucine reamination, the splanchnic bed for ≈15% and ≈15%, and
the kidneys for ≈12% and ≈18%, respectively (Fig. 2B). The sum of
the percent contributions by the 3 organs, to body leucine deami-
nation to KIC was ≈87%, while that of KIC reamination to leucine
was ≈112%.
Leucine flux through oxidation, deamination, and reamination
The sum of leucine deamination (the F7 model parameter) and
leucine oxidation (F9), as well as the sum of reamination (F8) and
1Supplementary data are available with the article through the journal Web site at http://nrcresearchpress.com/doi/suppl/10.1139/cjpp-2017-0439.
Fig. 1. Rates of whole-body leucine deamination to ketoisocaproic
acid (KIC) (i.e., of the KIC derived from leucine) calculated using
either Model 1 (from Matthews et al. 1993) or from Model 2 (eqs. 4 to 6
of the compartmental model). Data are means ± SE of 10 subjects.
The deamination data calculated with the 2 models were virtually
identical (p > 0.85 by paired t test).
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oxidation, expressed both as "mol·min−1 and as percentage of
whole-body rates, are reported in Table 2. In absolute terms, skel-
etal muscle accounted for the largest portion of these rates in
respect to those of the whole body, about 4-fold greater than those
of either the splanchnic bed or the kidneys. In relative terms, the
sum of the 3 sampled districts accounted for ≈80% (for F7+F8), and
for 93% (for F8+F9), of the corresponding whole-body rates.
The ratios of leucine oxidation (F9) to deamination (F7), and that
of leucine oxidation to reamination (F8), are reported in Fig. 3.
These ratios indicate the fraction of leucine irreversible loss (through
oxidation), over either leucine deamination to KIC (Fig. 3A), or KIC
reamination to leucine (Fig. 3B), and they can approximate the
“metabolon” concept in vivo across the 3 sampled organs. In the
kidneys, percent leucine oxidation over either deamination (55% ±
16%) or reamination (119% ± 47%), was >3-fold greater than the
Fig. 2. (A) Rates of leucine deamination to !–ketoisocaproate, KIC (Leu¡KIC), and of KIC reamination to leucine (KIC¡Leu), across total
skeletal muscle (n = 10), the splanchnic bed (n = 8), the kidneys (n = 7), as well as in the whole body. Rates are expressed as "mol·min−1. Levels
of the statistically significant difference between deamination and reamination (by the Wilcoxon paired t test) within each organ, as well as in
the whole body, are reported. Data are shown as means ± SE. (B) Percent contributions to the whole body, of leucine deamination to !-ketoisocaproate,
KIC (Leu¡KIC), and of KIC reamination to leucine (KIC¡Leu), across total skeletal muscle (n = 10), the splanchnic bed (n = 8) and the kidneys
(n = 7), as well as the sum of the percentages of the 3 organs. The reported levels of statistical significance indicate the differences (by the one-way
ANOVA and the Newman–Keuls post hoc test) between rates in either the splanchnic bed or the kidneys, and the corresponding ones in
skeletal muscle. The sum of rates from the 3 organs are reported as gross means (i.e., without SE), because not all subjects were studied across
all the 3 organs. The sum of either deamination or reamination are not significantly different from 100% (p > 0.7). Data are shown as means ± SE.
NS, not significant.
Table 1. Whole-body leucine kinetics either derived from






Leu C Ra 120 122
Leu N Ra 155 174
Leu Ox 21 23
Leu to KIC (= deamination) 56 87
KIC to Leu (= reamination) 35 58
Note: KIC, ketoisocaproic acid.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Garibotto et al. 3
Published by NRC Research Press
T1-T2
F3
rich2/jpp-cjpp/jpp-cjpp/jpp99914/jpp0903d14z xppws S!3 2/13/18 10:31 Art: cjpp-2017-0439 Input-1st disk, 2nd ??
corresponding values calculated across both the skeletal muscle
(15% ± 3% and 23% ± 8% for deamination and reamination, p < 0.04
and p < 0.01, respectively) and the splanchnic bed (17% ± 7% and
36% ± 17%, p < 0.005 and p < 0.04, respectively) (Figs. 3A and 3B).
These data indicate that, in the kidneys, leucine is preferentially
oxidized, to a much larger extent than that observed in either the
skeletal muscle or the splanchnic area.
Discussion
BCAA metabolism in humans is tightly regulated to maintain
levels sufficiently high to support major functions, such as pro-
tein synthesis, provision of nitrogen for the synthesis of nones-
sential amino acids and hormone-like signals, but at the same
time excess levels are prevented by the upregulation of irrevers-
ible disposal pathways (Suryawan et al. 1998). Four major observa-
tions can be drawn from this study. First, in post-absorptive
human beings, skeletal muscle accounts for the largest fraction of
body BCAA leucine deamination and reamination, even larger
than that expected from tissue BCAA-Tm distribution (Suryawan
et al. 1998). Second, a relevant fraction (≈30%–35%) of these rates is
accounted for by visceral organs (splanchnic bed and kidneys).
Third, skeletal muscle and visceral organs together virtually account
for body total leucine deamination and reamination. Fourth, in the
kidneys, leucine is preferentially channeled towards oxidation
rather than to reamination.
Overall, our in vivo data demonstrate that skeletal muscle plays
a major role in overall leucine metabolism. The high percentage
of body leucine deamination and oxidation accounted for by skel-
etal muscle, in agreement with the concept that the BCAAs are
predominantly catabolized by extrahepatic tissues, as also sug-
gested by their low first-pass splanchnic extraction (Biolo et al.
1992; Matthews et al. 1993; Stoll et al. 1998). Also leucine oxidation
took place to a large extent in skeletal muscle (≈37% of whole-body
rates), as previously reported (Tessari et al. 1996). Of note, the high
rates of leucine deamination and reamination in muscle can pro-
vide nitrogen for the synthesis of nonessential amino acids such
as alanine and glutamine, the key nitrogen carriers from the pe-
riphery (skeletal muscle) to the liver.
We observed that in the whole body, leucine deamination is
6- to 7-fold faster than oxidation (Tessari et al. 1996), a finding
similar to what was previously observed for valine also (Staten
et al. 1984). A similar leucine deamination/oxidation ratio is ob-
served in skeletal muscle and in splanchnic organs. These data
suggest that in muscle and splanchnic organs the transamination
step may regulate the free levels of the individual BCAA’s, while
decarboxylation limits their catabolism. Contrariwise, the leucine
deamination and oxidation rates are similar in the kidney.
A new finding of this study is that the contribution by visceral
organs to whole-body leucine deamination and reamination rates
is substantial (about one third of total), and almost equally shared
by kidneys and splanchnic organs. In the fetal kidney, BCAA trans-
port is necessary for early nutrition and development (Guetg et al.
2015). The adult kidney, in particular in the medullary thick as-
cending limb, is rich in all the enzymatic machinery involved in
leucine catabolism and (or) oxidation. Oxidation of leucine in this
nephron segment may provide energy to sustain active ion trans-
port (Tring-Trang-Tan et al. 1988).
The liver is thought to be the primary site for the oxidation of
branched-chain keto acid (BCKA) but not BCAA (Brosnan and
Brosnan 2006). In this study, the contribution of splanchnic or-
Table 2. The sum of leucine deamination (F7 model parameter) and of leucine oxidation
(F9 model parameter) (in "mol·min−1), as well as of leucine reamination (F8) and oxidation
(F9), across each of the 3 sampled districts and in the whole body, and their percentage











Leu Deam. (F7) + Ox (F9) 55.1±7.7 13.8±5.1 13.6±2.3 125.1±15.6
(F7+F9) as % whole body 53.1±10.9 14.0±6.3 12.9±3.2 ≈80%
Leu Ream. (F8) + Ox (F9) 46.4±6.7 8.9±3.5 13.1±2.3 91.5±17.4
(F8+F9) as % whole body 62.1±10.5 14.2±7.3 17.3±3.8 ≈93%
Note: Values are means ± SE.
Fig. 3. (A) The percentage of leucine oxidation (F9 model parameter) vs.
deamination (F7) of each organ as well as in the whole body (WB).
The reported p values indicate the level of the significant differences
between either total skeletal muscle (SM, n = 10), or the splanchnic
bed (SB, n = 7) and the kidneys (KD, n = 6), calculated by the
one-way ANOVA and the Newman–Keuls post hoc test). Whole body
ratios (n = 10) are also reported. Data are shown as Means ± SE.
(B) The percentage of leucine oxidation (F9 model parameter) vs.
reamination (F8) of each organ as well as in the WB. The reported
p values indicate the level of the significant differences between
either total SM (n = 10), or the SB (n = 7) and the KD (n = 7), calculated
by the one-way ANOVA and the Newman–Keuls post hoc test). WB
ratios (n = 10) are also reported. Data are shown as means ± SE.
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gans to whole-body leucine deamination and reamination rate
was greater than expected ("15%). However, we could not evaluate
the oxidation of KIC to beta-hydroxy-beta-methylbutyrate by the
enzyme KIC dioxygenase, a reaction which takes predominantly
in the liver. In liver rats, it has been observed that a minor percentage
(about 5%) of daily leucine metabolism is channeled through the
dioxygenase pathway (Van Koevering and Nissen 1992).
Sites other than muscle and visceral organs, such as adipose
tissue, brain, heart, and lung (that could not be sampled in our
study), should contribute minimally to leucine metabolism. How-
ever, concerning body fat, it should be considered that the data
derived from skeletal muscle (i.e., leg) catheterization also include
the contributions of both intramuscular and subcutaneous adi-
pose tissue (Frick et al. 1988).
One original contribution of our study is the investigation of
the relative roles of leucine deamination, reamination, and oxi-
dation, both in the whole body and in selected organs in humans.
By such data presentation, we intended to depict a sort of leucine
“metabolon” in humans. Nevertheless, we are fully aware that the
transfer of the “metabolon” concept into the in vivo human set-
ting is rather complex, and perhaps not entirely appropriate. One
example and (or) limitation of such a transfer is given by the
precursor substrate(s) of renal leucine oxidation. Because in the
kidneys leucine deamination and reamination rates were not sta-
tistically different from each other, leucine oxidation in the kid-
neys (≈4.5 "mol·min−1, unreported data) should have predominantly
derived from other, unaccounted sources: one would likely be KIC
itself. Indeed, as reported previously (Garibotto et al. 2002), there
was a net KIC uptake by the kidneys, of ≈3.3 "mol·min−1 (using
plasma data), a figure that, added to the net (albeit insignificant)
difference between deamination and reamination (≈0.5 "mol·min−1),
yields a total of 3.8 "mol·min−1, that would account for ≈85% of
renal total leucine oxidation. Therefore, should leucine oxidation
in the kidneys predominantly derive from the KIC taken up (i.e.,
not from leucine deamination itself), thus directly entering the
mitochondria for oxidation, this other oxidation route may not be
strictly considered under the “metabolon” concept. On the other
hand, the limitation of our model and (or) approach is intrinsi-
cally linked to the complexity of the studies in humans.
Another feature of BCAAs is the role of leucine as an anabolic
nutrient signal to stimulate protein synthesis by activation of
mTORC1, an effect reinforced by physical exercise and protein
feeding. Several conditions causing wasting, such as sarcopenia of
aging and inflammation, blunt the leucine-induced mTORC1
1 activation (Ham et al. 2014). A limitation of our study is that we
evaluated leucine deamination only in the post-absorptive, basal
state. In addition, our patients were studied at rest, and the effects
of physical exercise on leucine metabolism have not therefore
been addressed.
The understanding of BCAA/Tm-BCKD activity in individual or-
gans and in the whole body in disease is of major importance in
several clinical fields. Elevated levels of BCAAs are implicated in
obesity, insulin resistance, and type 2 diabetes (Adams 2011). An
emergent hypothesis is that in obese, insulin-resistant state or in
type 2 diabetes, raised BCAA and BCKA levels reflect reduced
BCAA/Tm-BCKD activity in a variety of metabolically relevant tis-
sues such as liver, WAT, and possibly muscle (Adams 2011). How-
ever, this hypothesis still needs to be confirmed in human studies.
It is interesting that in animal models, liver BCKD activity can be
modulated by protein intake (Brosnan and Brosnan 2006). Should
this take place also in humans, changes in the amounts or quality
of ingested protein could influence BCKD activity in different
tissues to correct the alterations in BCAA/BCKA pattern in insulin-
resistant states.
Further studies are required to understand mechanism and me-
diators that regulate deamination and reamination rates in sepsis.
During sepsis, accelerated protein degradation is associated with
increased transamination and oxidation of amino acids in skeletal
muscle (Woolf et al. 1979). Reamination of KIC to leucine has also
been shown to be enhanced in the liver of starved and endotoxin-
treated rats (Holecek et al. 2001).
BCAA deamination and transamination is also a potential ma-
jor topic in patients with chronic kidney disease (CKD). Our find-
ing of preferential leucine/KIC degradation in the human kidney
suggests that progressive CKD may be associated with reduced
requirement for leucine. This observation may explain, at least in
part, the good nutritional status achieved even with very low
protein diets in non-dialyzed patients with CKD (Bellizzi et al.
2016). Of note, supplemented very low protein diets (0.28–
0.40 g·kg−1) containing BCKAs are offered to CKD patients to pro-
vide EAA precursors without the nitrogen load from EAAs. These
supplemented very low protein diets appear to generate less toxic
metabolic products than similar amounts of protein from LPDs
(Gao et al. 2010) and have proven to be effective and safe when
postponing dialysis treatment in elderly CKD patients (Bellizzi
et al. 2016). However, the optimal doses of keto-acids and the
muscle and systemic adaptations to keto acid supplementation
are still unresolved.
In conclusion, this study provides estimates of leucine deami-
nation, reamination, and oxidation in the skeletal muscle, the
splanchnic bed, and the kidneys, as well as in the whole body in
the post-absorptive state, in humans. Whereas in absolute terms,
the most relevant contributions are provided by skeletal muscle;
in relative terms, the kidney plays a remarkable role particularly
in leucine oxidation. The data here presented could be of help in
the understanding of whole-body as well as organ leucine metab-
olism, and they can ultimately lead to a better modeling of amino
acid metabolism. They may also be important in the calculation of
the amount of leucine effectively delivered to tissues, both from a
nutritional standpoint and for the associated signaling effect.
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